

**Amendments to the Claims:**

This listing of the claims will replace all prior version, and listings, of claims in the application:

**Corrected Listing of Claims:**

1. (Previously Presented) A modified gp120 polypeptide comprising portions of at least two conserved regions of an envelope protein selected from a the group of lentiviruses consisting of HIV-1, HIV-2 and SIV, wherein at least one of the following changes relative to the wild-type gp120 protein is made:

- (a) introduction of disulfide bonds to decrease the free energy of folding relative to the wild type gp120 protein ;
- (b) filling a cavity of the gp120 protein with hydrophobic amino acid residues; or
- (c) introducing a Pro residue at a defined turn structure;

wherein the modified polypeptide maintains the overall 3-dimensional structure of a discontinuous conserved epitope of the wild-type gp120, wherein the discontinuous conserved epitope is a CD4BS epitope, CD4i epitope or 2G12 epitope.

2. (Original) The modified gp120 polypeptide of claim 1, wherein the discontinuous conserved epitope is a CD4BS epitope or CD4i epitope.

3. (Canceled)

4. (Currently Amended) The modified gp120 polypeptide of ~~claim 1~~claim 3, wherein the gp120 protein is HIV-1.

5. (Original) The modified gp120 polypeptide of claim 4, wherein disulfide bonds are introduced between at least one of the groups of amino acids that correspond to Pro118-Ala443, Leu122-Gly431, Phe210-Gly30, or Ser256-Phe376 of the HIV-1 HXBc2 strain.

6. (Original) The modified gp120 polypeptide of claims 4 or 5, wherein at least one amino acid residue corresponding to wild-type gp120 Ser375, Val255, Arg273, Ser481, Ser447, Asn377 of the HIV-1 HXBc2 strain, Thr283, or Asp477 of the HIV-1 HXBc2 strain, has been substituted with a hydrophobic amino acid residue.

7. (Original) The modified gp120 polypeptide of claim 6, wherein at least one of the following amino acid substitutions is present:

Trp for Ser375, Val255 or Arg 273;

Phe for Ser481;

Ile for Ser447 or Thr283;

Or Leu for Asn377 or Thr283.

8. (Original) The modified gp120 polypeptide of claim 6, wherein a Pro residue has been introduced at a defined turn structure.

9. (Original) The modified gp120 polypeptide of claim 5, wherein a Pro residue has been introduced at a defined turn structure.

10. (Original) The modified gp120 polypeptide of claim 4, wherein a Pro residue has been introduced at a defined turn structure.

11. (Original) The modified gp120 polypeptide of claim 8, wherein a Pro residue has been substituted for Ile423.

12. (Original) The modified gp120 polypeptide of claim 9, wherein a Pro residue has been substituted for Ile423.

13. (Original) The modified gp120 polypeptide of claim 10, wherein Pro has been substituted for Ile423.

14. (Original) The modified gp120 polypeptide of claim 1, wherein at least two of the changes have been made.

15. (Canceled)

16. (Currently Amended) The modified gp120 polypeptide of claim 1 ~~claim 1-5~~, wherein at least three of the changes have been made.

17. (Previously Presented) The modified gp120 polypeptide of claim 1 wherein the cavity of the gp120 protein corresponds to Phe43 of the wild type HIV-1, HXBc2 strain.